A Study of the Safety and Tolerability of GTX-102 in Children With Angelman Syndrome (KIK-AS)

  • STATUS
    Recruiting
  • End date
    Jan 24, 2023
  • participants needed
    20
  • sponsor
    GeneTX Biotherapeutics, LLC
Updated on 17 March 2022

Summary

This is a Phase 1/2, open-label, multiple-dose, study to evaluate the safety, tolerability, and plasma and cerebrospinal fluid (CSF) concentrations of GTX-102 in pediatric patients with Angelman syndrome. Up to 20 patients (male and female) ≥ 4 and ≤ 17 years of age with a genetically confirmed diagnosis of full maternal UBE3A gene deletion (within 15q11.2-q13 region) will be enrolled.

Description

This is a Phase 1/2, open-label, multiple-dose, study to evaluate the safety, tolerability, and plasma and CSF concentrations of GTX-102 in pediatric patients with AS.

The study includes a monthly dosing period followed by a maintenance period. Eligible patients who meet all of the inclusion criteria and none of the exclusion criteria and who successfully complete all screening and baseline assessments will be assigned to one of 2 dose cohorts based on patient age in Canada and UK; in the US all patients will enter a single dose cohort. GTX-102 will be administered by intrathecal (IT) injection via lumbar puncture (LP) at Baseline followed by 2-3 subsequent IT injections on study Days 30, 58 and 86. The procedure for IT administration of GTX-102 will performed by a clinician with experience in LP and anesthetic care will be directed by experienced anesthesiologists with a focus on patient safety and comfort. The duration of study for each patient in the dose escalation phase is anticipated to be approximately 5 months. Patients will then transition to a maintenance phase of study where they may receive continued treatment with GTX-102.

Details
Condition Angelman Syndrome
Treatment GTX-102
Clinical Study IdentifierNCT04259281
SponsorGeneTX Biotherapeutics, LLC
Last Modified on17 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Signed informed consent from parent(s) or legal guardian(s)
Documented genetic confirmation of full maternal UBE3A gene deletion causing AS (e.g. DNA methylation testing with either a chromosomal microarray or FISH) in the region of 15q11.2-q13 including class I, II or III)
Age ≥ 4 to ≤ 17 years at screening (in US Age ≥ 4 to < 8 years at screening)
Stable seizure control (defined as clinically stable with no changes in antiepileptic medications over the prior 1 month before screening visit, other than weight associated dose adjustments)
Platelet count, prothrombin time (PT) / international normalized ratio (INR) and partial thromboplastin time (PTT) within normal limits
Normal renal function with serum creatinine and spot urine protein within normal limits
Normal hepatic function with total bilirubin, aspartate aminotransferase (AST),alanine aminotransferase (ALT) and alkaline phosphatase within normal limits
Willing and able to comply with scheduled visits, drug administration plan, laboratory tests, study restrictions, and all study procedures LP
Able to tolerate the anesthetic regimen required for LP procedure

Exclusion Criteria

Any change in medications (excluding antiepileptic drugs) or diet intended to treat symptoms of AS (e.g. sleeping aids, supplements, ketogenic or low-glycemic index diet, other) over the prior 3 months before screening
Inability to ambulate independently or with an assistive device or caregiver hand-hold
Any bleeding or platelet disorder
Any clinically significant (CS) cardiovascular, endocrine, hepatic, renal, pulmonary, gastrointestinal, neurologic, malignant, metabolic, psychiatric, or other condition that, in the judgment of the Investigator, will pose a safety risk, will make the patient unsuitable for participation in, and/or unable to complete the study procedures
Any laboratory abnormality, that, in the Investigator's opinion, could adversely affect the safety of the patient, make it unlikely that the course of treatment or follow up would be completed, or impair the assessment of study result
Any active infection
Bone, spine, bleeding, or other disorder that exposes the patient to risk of injury or unsuccessful lumbar puncture
Drugs that increase the risk of bleeding (e.g. heparin, low molecular weight heparin, platelet inhibitors)
Use of any investigational oligonucleotide in the past 6 months
Any prior use of gene therapy
Use of any investigational drugs in the past 6 months
Any medical condition that would require intubation for the anesthesia procedure
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note